Richard Jirui Lin
Affiliations: | 2000 | University of California, San Diego, La Jolla, CA |
Google:
"Richard Lin"Mean distance: 17.34 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Ronald M. Evans | grad student | 2000 | UCSD | |
| (Transcriptional silencing in the molecular pathogenesis of acute promyelocytic leukemia.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin RJ, Baser RE, Elko TA, et al. (2020) Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation |
| Olin RL, Fretham C, Pasquini MC, et al. (2020) Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Advances. 4: 2810-2820 |
| Lin RJ, Ho C, Devlin SM, et al. (2020) Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation |
| Lin RJ, Michaud L, Lobaugh SM, et al. (2020) The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leukemia & Lymphoma. 1-9 |
| Lin RJ, Cohen AG, Stabler SM, et al. (2020) Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine |
| Peled JU, Gomes ALC, Devlin SM, et al. (2020) Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. The New England Journal of Medicine. 382: 822-834 |
| Lin RJ, Lobaugh SM, Pennisi M, et al. (2020) Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma. Haematologica |
| Pennisi M, Cho C, Devlin SM, et al. (2020) Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores. Biology of Blood and Marrow Transplantation. 26 |
| Shouval R, Fein JA, Devlin SM, et al. (2020) The Impact of Individual Co-Morbidities in Myeloablative Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 26: S141 |
| Brambilla CZ, Ruiz JD, Lobaugh SM, et al. (2020) Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy Biology of Blood and Marrow Transplantation. 26: S97-S98 |